Key Highlights
- Fusion Antibodies LSE:FAB is shown up 4.55% on 21 September 2026.
- The company reported FY26 Revenue of £2.1 million, up from £1.97 million.
- Underlying service revenue reached £1.86 million, with H2 service revenue 21% higher than H1.
- Gross Margin increased substantially to 58.3% from 22% after the company's results were corrected on 15 September.
- The operating loss narrowed to £1.13 million from a restated £1.63 million.
- OptiMAL was commercially launched in December 2025 and continues to be developed as a proprietary antibody-design technology.
- Fusion Antibodies recently secured a Canadian Patent for OptiMAL, adding to its international intellectual-property position.
- The company ended FY26 with approximately £1.04 million in cash after raising about £1.4 million earlier in 2026.
Why Is Fusion Antibodies LSE:FAB in Focus on 21 September 2026?
Fusion Antibodies LSE:FAB is attracting attention after gaining 4.55% on 21 September 2026, according to the market-mover data provided.
The move comes shortly after the company's FY26 final results, which showed modest revenue growth but a much larger improvement in gross margin and a narrower operating loss. The results also highlighted progress in the commercialisation of OptiMAL, the company's proprietary antibody-design technology.
For investors following LSE:FAB, the key issue is whether these improvements can translate into sustained revenue growth and a further reduction in operating losses during FY27.
Why Did Fusion Antibodies LSE:FAB Rise 4.55% Today?
The 4.55% increase on 21 September 2026 follows a period of heightened trading activity around the company's September results.
There is no confirmed company statement identifying one specific reason for today's entire move. However, Fusion Antibodies has recently reported its FY26 results, received a Canadian patent for OptiMAL and continued to highlight commercial opportunities in antibody discovery, engineering and diagnostics.
Trading data show that the shares also experienced substantial activity around the September results, including a 16.22% rise on 15 September following a sharp decline on results day.
This recent Volatility indicates that investors are closely assessing the company's financial performance and commercial prospects.
What Were Fusion Antibodies' Latest Financial Results?
Fusion Antibodies reported FY26 revenue of £2.1 million, compared with £1.97 million in FY25.
Underlying service revenue was £1.86 million, with second-half revenue 21% higher than the first half. The company also recorded £872,000 of other operating income, primarily related to grant funding.
The most notable financial improvement was gross margin. The amended results reported a 58.3% gross margin, compared with 22% in the previous year.
The operating loss narrowed to £1.13 million, versus a restated £1.63 million loss previously.
This combination of higher revenue and improved gross margin is one of the main reasons LSE:FAB remains under market attention.
Why Is OptiMAL Important for LSE:FAB?
OptiMAL is central to Fusion Antibodies' longer-term commercial strategy.
The technology is designed to support antibody discovery, affinity maturation and sequence optimisation. It was commercially launched in December 2025 following continued validation work involving the US National Cancer Institute.
The company is seeking to establish OptiMAL as an additional technology-led revenue opportunity alongside its established contract research activities.
The commercial development of the platform is therefore an important area to monitor during FY27.
What Does the New Canadian Patent Mean for Fusion Antibodies?
Fusion Antibodies announced in September that its Canadian patent application for OptiMAL had been granted.
The patent covers two antibody families and aspects of their design methodology. The company is also pursuing additional patent applications for its OptiMAL library in other international territories.
The expansion of intellectual-property protection is relevant because proprietary technology can potentially support future licensing, collaboration and commercialisation opportunities.
The key question for investors is how effectively the protected technology can ultimately translate into commercial contracts and recurring revenue.
Could Improving Margins Remain Important for LSE:FAB?
Margin development is likely to remain an important metric.
The substantial increase in gross margin during FY26 was attributed to a greater focus on higher-margin work and improved cost control across client projects.
However, administrative expenses increased during the year, partly reflecting activity associated with grant-funded programmes. This means investors may continue watching the relationship between revenue growth, Gross Profit and operating expenses.
A sustained improvement in Operating Leverage would provide a different financial profile from the company's earlier development period.
What Should Investors Watch Next for LSE:FAB?
Several factors could remain important during the remainder of 2026 and into FY27.
The first is OptiMAL commercialisation, including customer adoption, partnerships and potential licensing or technology-related agreements.
The second is the company's underlying service revenue. Investors may monitor whether H2's stronger performance continues rather than relying on one-off intellectual-property income.
The third is profitability. Further improvement in gross margin and a reduction in the operating loss could become increasingly important as the Business scales.
The company's cash position will also remain relevant because continued research, development and commercialisation require funding.
Could Fusion Antibodies LSE:FAB Remain in Focus After the 4.55% Rise?
The 4.55% gain on 21 September 2026 comes at a significant point for Fusion Antibodies.
The latest results show revenue growth, a major improvement in gross margin and a narrower operating loss, while OptiMAL provides a potentially important technology-led growth opportunity. The recent Canadian patent adds further intellectual-property protection.
The next phase for LSE:FAB is therefore likely to centre on commercial execution: converting its antibody-development capabilities and OptiMAL technology into higher Recurring Revenue while controlling costs and improving profitability.






Please wait processing your request...